Kovack Advisors Inc. Has $4.76 Million Holdings in Johnson & Johnson $JNJ

Kovack Advisors Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 16.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,667 shares of the company’s stock after selling 5,055 shares during the quarter. Kovack Advisors Inc.’s holdings in Johnson & Johnson were worth $4,759,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth about $26,000. Evolution Wealth Management Inc. acquired a new stake in Johnson & Johnson in the second quarter valued at $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $28,000. Semmax Financial Advisors Inc. lifted its holdings in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the period. Finally, Compass Financial Services Inc grew its position in shares of Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after buying an additional 198 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J is preparing a potential sale of its planned orthopedics unit that could fetch about $20 billion; interest from large buyout firms suggests the company could unlock material value and simplify its planned separation strategy. Read More.
• Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania — expands U.S. manufacturing capacity for oncology/cell therapies and supports longer‑term revenue potential. Read More.
• Positive Sentiment: Clinical and regulatory progress for RYBREVANT FASPRO: new Phase 1b/2 data reported strong response rates (56% ORR) in first‑line recurrent/metastatic head‑and‑neck cancer, building on an FDA Breakthrough Therapy Designation — positive for the oncology growth outlook if confirmatory trials succeed. Read More.
• Positive Sentiment: Dividend increase and continued appeal to income investors — J&J raised its quarterly payout, reinforcing cash return policy and supporting demand from dividend‑focused holders. Read More.
• Neutral Sentiment: Options activity and elevated street coverage have picked up, which can amplify short‑term moves but doesn’t change fundamentals by itself — watch for large directional trades. Read More.
• Neutral Sentiment: Analyst/retail attention (Zacks, TipRanks) is keeping JNJ in focus; useful for sentiment but incremental to earnings and pipeline catalysts. Read More.
• Negative Sentiment: Senior executives disclosed recent stock sales (several Form 4 filings), which investors sometimes view as a mild negative signal about near‑term insider conviction. Read More.
• Negative Sentiment: Ongoing talc litigation and verdict coverage remain a material legal overhang that can constrain J&J’s valuation multiple despite operational/clinical positives. Read More.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on JNJ. Argus upped their target price on Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. The Goldman Sachs Group restated a “buy” rating and issued a $250.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 22nd. TD Cowen increased their price objective on shares of Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Finally, Wolfe Research upped their price target on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Trading Up 0.8%

JNJ opened at $246.90 on Friday. The firm has a market capitalization of $595.00 billion, a PE ratio of 22.34, a P/E/G ratio of 2.38 and a beta of 0.35. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $246.96. The company’s 50-day moving average is $220.45 and its 200 day moving average is $198.55.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The firm had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.